RESUMEN

Objetiva, aceptable, repetible y útil, la espirometría continúa siendo un elemento diagnóstico fundamental en la atención del enfermo respiratorio. Muy a pesar de los avances en la informática que han facilitado su uso e interpretación, continúa siendo poco utilizada en consultorios y hospitales. Este artículo pretende introducir al lector con los elementos teóricos fundamentales para su interpretación, al mismo tiempo comprender sus limitaciones e indicaciones con el objeto de facilitar y estimular su empleo. Finalmente se enfoca el momento de indicar otras pruebas diagnósticas complementarias más sofisticadas, con el afán de contribuir a ofrecer un diagnóstico precoz y al tratamiento efectivo del enfermo respiratorio

PALABRAS CLAVE

Espirometría, enfermedad respiratoria.

REFERENCIAS

1. Murray CJ, Lopez AD. Evidence-based health policy-lessons from the Global Burden of Disease. Study. Science 1996: 274: 740-743.

2. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349: 1436-1442.

3. Hoogendoorn M, Rutten-van Molken MP, Hoogenveen RT, van Genugten ML, Buist AS, Wouters EF, Feenstra TL. A dynamic population model of disease progression in COPD. Eur Respir J 2005; 26: 223-233.

4. Menezes AM, Perez-Padilla R, Jardim JR, Muino A, Lopez MV, Valdivia G, Montes de Oca M, Talamo C, Hallal PC, Victora CG. PLATINO Team. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 2005; 366: 1875-81.

5. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-1276.

6. Kannel WB, Hubert H, Lew EA. Vital capacity as a predictor of cardiovascular disease: the Framingham study. Am Heart J 1983; 105: 311-315.

7. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994; 272: 1497-1505.

8. Currie GP, Legge JS. ABC of Chronic Obstructive Pulmonary Disease. BMJ 2006; 332: 1261-1263.

9. Similowski T, Dore MF, Marazzini L, Orvoen-Frija E, D’Angelo E, Derenne JP, Milic-Emili J. Forced expiration. Various current concepts, 50 years after Robert Tiffeneau. Rev Mal Respir. 1997; 14(6): 431-43.

10. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CPM, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, Mc Kay R, Navajas D, Federsen OF, Pellegrino R, Viegi G, Wanger J. General Considerations for Lung Function Testing. Eur Respir J 2005; 26: 153-161.

11. Pérez-Padilla R, Valdivia G, Muiño A, López MV, Márquez MN, Montes de Oca M, Tálamo C, Lisboa C, Pertuzé J, Jardim JRB, Menezes AMB. Valores de referencia espirométrica en 5 grandes ciudades de Latinoamérica para sujetos de 40 ó más años de edad. Arch Bronconeumol 2006; 42: 317-325.

12. Hankinson JL, Odencratz JR, Fedan KB. Spirometric reference values from a sample of the general US population. Am J Respir Crit Care Med 1999; 159: 179-187.

13. Wang X, Dockery DW, Wypij D, Fay ME, Ferris BG jr. Pulmonary function between 6-18 years of age. Pediatr Pulmonol 1993; 15: 75-88.

14. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Standardization of lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J 1993; 6: Suppl. 16, 5-40.

15. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CPM, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, Mc Kay R, Navajas D, Federsen OF, Pellegrino R, Viegi G, Wanger J. Standardization of spirometry. Eur Respir J 2005; 26: 319-338.

16. Enright PL, Studnicka M, Zielinski J. Spirometry to detect and manage chronic obstructive pulmonary disease and asthma in the primary care setting. Eur Respir Mon 2005; 31: 1-14.

17. American Thoracic Society. Lung Function Testing: Selection of Reference Values and Interpretative Strategies. Am Rev Respir Dis 1991; 144: 1202-1218.

18. American Thoracic Society. Evaluation of impairment/disability secondary to respiratory disorders. Am Rev Respir Dis 1986; 133: 1205-1209.

19. Empey DW. Assessment of upper airways obstruction. BMJ 1972; 3: 503-505.

20. Wasserman RL, Baker JW, Kim KT, Blake KV, Scott CA, Wu W, Faris MA, Crim C. Efficacy and safety of inhaled fluticasone propionate chlorofluorocarbon in 2-to 4-year-old patients with asthma: results of a double-blind, placebo-controlled study. Ann Allergy Asthma Immunol 2006; 96: 808-18.

21. Brand PL, Duiverman EJ, Waalkens HJ, van Essen-Zandvliet EE, Kerrebijn KF. Peak flow variation in childhood asthma: correlation with symptoms, airways obstruction, and hyperresponsiveness during long-term treatment with inhaled corticosteroids. Dutch CNSLD Study Group. Thorax 1999; 54: 103-7.

22. Brauer AF, Roorda RJ, Brand L. Home spirometry and asthma severity in children. Eur Respir J 2006. http://erj.ersjournals.com/cgi/rapidpdf/ 09031936.06.00118205v1.pdf